Development of a high-throughput human rhinovirus infectivity cell-based assay for identifying antiviral compounds

Journal of Virological Methods

Volumn 173, Issue 2, 2011, Pages 182-188

  Phillips, Tim ^a   Jenkinson, Lesley ^a,c   McCrae, Christopher ^b   Thong, Bob ^a   Unitt, John ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c MEDIMMUNE   (United States)

Author keywords

Antiviral agents; CellTiter Glo; Cytopathic effect; HeLa OHIO; High throughput screen; HRV serotypes; HTS; Human rhinovirus

Indexed keywords

ANTIVIRUS AGENT; BTA 798; PIRODAVIR; PLECONARIL; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; EPITHELIUM CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS; IC 50; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTYPE; VIRUS INFECTIVITY; VIRUS REPLICATION;

HUMAN RHINOVIRUS SP.;

EID: 79954590732     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.02.002     Document Type: Article

References (29)

1. Andries K., Dewindt B., Snoeks J., Willebrords R., Van Eemeren K., Stokbroekx R., Janssen P.A.J. In vitro activity of pirodavir (R77975), a substituted phenoxy-pyridazinamide with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 1992, 36:100-107.
2. Barnard D.L., Hubbard V.D., Smee D.F., Sidwell R.W., Watson K.G.W., Tucker S.P.T., Reece P.A.R. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to Pirodavir: novel caspid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 2004, 48:1766-1772.
3. Baud M. Data analysis, mathematical modeling. Methods of Immunological Analysis, vol. 1: Fundamentals 1993, VCH Publishers Inc., New York. R.F. Masseheff (Ed.).
4. Campbell C.E., Laane M.M., Haugarvoll E., Giaever I. Monitoring viral-induced cell death using electric cell-substrate impedance sensing. Biosens. Bioelectron. 2007, 23:536-542.
5. Chu J.J.H., Yang P.L. C-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc. Natl. Acad. Sci. USA 2007, 104:3520-3525.
6. De Palma A.M., Vliegen I., De Clercq E., Neyts J. Selective inhibitors of piconarvirus replication. Med. Res. Rev. 2008, 28:823-884.
7. Gern J.E. Rhinovirus and the initiation of asthma. Curr. Opin. Allergy Clin. Immunol. 2009, 9:73-78.
8. Hayden F.G., Herrington D.T., Coats T.L., Kim K., Cooper E.C., Villano S.A., Liu S., Hudson S., Pevear D.C., Collett M., McKinlay M. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin. Infect. Dis. 2003, 36:1523-1532.
9. Hofer F., Gruenberger M., Kowalski H., Machat H., Huettinger M., Kuechler E., Blaas D. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc. Natl. Acad. Sci. USA 1994, 91:1839-1842.
10. Iro M., Witteveldt J., Augus A.G.N., Woerz I., Kaul A., Bartenschlager R., Patel A.H. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res. 2009, 83:148-155.
11. Jackson D.J., Johnston S.L. The role of viruses in acute exacerbations of asthma. J. Allergy Clin. Immunol. 2010, 125:1178-1187.
12. Last-Barney K., Marlin S.D., McNally E.J., Cahill C., Jeanfavre D., Faanes R.B., Merluzzi V.J. Detection of major group rhinoviruses by soluble intercellular adhesion molecule-1 (sICAM-1). J. Virol. Methods 1991, 35:255-264.
13. Ledford R.M., Patel N.R., Demenczuk T.M., Watanyar A., Herbertz T., Collet M.S., Pevear D.C. VP1 sequencing of all human rhinovirus serotypes: insight into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J. Virol. 2004, 78:3663-3674.
14. Leung T.F., To M.Y., Yeung A.C.M., Wong Y.S., Wong G.W.K., Chan P.K.S. Multiplex molecular detection of respiratory pathogens in children with asthma exacerbation. Chest 2010, 137:348-354.
15. Li Q., Maddox C., Rasmussen L., Hobrath J.V., White L.E. Assay development and high-throughput anti-viral drug screening against Bluetongue virus. Antiviral Res. 2009, 83:267-273.
16. Mondal R., Koev G., Pilot-Matias T., He Y., Ng T., Kati W., Molla A. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well. Antiviral Res. 2009, 82:82-88.
17. Neumann E., Moser R., Snyers L., Blaas D., Hewat E.A. A cellular receptor of human rhyinovirus Type 2, the very low density lipoprotein receptor, binds to two neighboring proteins of viral capsid. J. Virol. 2003, 77:8504-8511.
18. Noah J.W., Severson W., Noah D.L., Rasmussen L., White E.L., Jonsson C.B. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res. 2007, 73:50-59.
19. Piralla A., Rovida F., Campanini G., Rognoni V., Marchi A., Locatelli F., Gerna G. Clinical severity and molecular typing of human rhinovirus C strains during a fall outbreak affecting hospitalized patients. J. Clin. Virol. 2009, 45:311-317.
20. Rohde G. Drug targets in rhinoviral infections. Infect. Disord.-Drug Targets 2009, 9:126-132.
21. Ryan J., Tucker S.P., Luttick A., Hamilton S., Nearn R.H. A new oral rhinovirus inhibitor BTA798. 18th Int. Conf. Antivir. Res. 2005, Abstract LB-11.
22. Seemungal T.A.R., Harper-Owen R., Bhowmik A., Jeffries D.L., Wedzicha J.A. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur. Respir. J. 2000, 16:677-683.
23. Severson W., Mcdowell M., Ananthan S., Chung D.-H., Rasmussen L., Sosa M.I., White E.L., Noah J., Jonssson C.B. High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2). J. Biomol. Screen. 2008, 13:879-887.
24. Simasek M., Blandino D.A. Treatment of the common cold. Am. Fam. Physician 2007, 75:515-522.
25. Smee D.F., Morrison A.C., Barnard D.L., Sidwell R.W. Comparison of colorimetric, fluorimetric and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J. Virol. Methods 2002, 106:71-79.
26. Uncapher C.R., Dewitt C.M., Colonno R.J. The major and minor group receptor families contain all but one human rhinovirus serotype. Virology 1991, 180:814-817.
27. van Rijt L.S., van Kessel C.H.G., Boogaard I., Lambrecht B.N. Respiratory viral infections and asthma pathogenesis: a critical role for dendritic cells. J. Clin. Virol. 2005, 34:161-169.
28. Yu X., Sainz B., Uprichard S.L. Development of a cell-based Hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening. Antimicrob. Agents Chemother. 2009, 53:4311-4319.
29. Zhang J.-H., Chung T.D.Y., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4:67-73.